Turtle Cameron sold $235K of SYRE
Turtle Cameron (Chief Executive Officer) sold 3,294 shares of Spyre Therapeutics, Inc. (SYRE) at $71.38 ($0.24M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The primary tradable element is the disclosed sale size and execution price; absent additional company news, it mainly informs sentiment rather than fundamentals.
Market read
Traders may monitor SYRE for short-term sentiment effects from insider selling, but 10b5-1 typically limits interpretive power.
What to watch
The filing does not reveal whether sales were part of routine scheduled selling, nor does it indicate remaining insider exposure changes beyond the post-transaction share count.
Background
This is an SEC Form 4 insider transaction disclosure for Spyre Therapeutics, reported as an open-market sale by the CEO under a Rule 10b5-1 plan.
Ticker impact
Spyre Therapeutics CEO Turtle Cameron sold 3,294 shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Low-to-moderate downside bias intraday/near-term if market interprets as bearish, but magnitude likely muted by 10b5-1 context.
The filing provides a concrete sale price/value and confirms a pre-arranged plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
Minimal; this is company-specific insider activity with no stated operational/regulatory/clinical catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, the market may overreact; price may mean-revert if no other negative catalysts emerge.
Key entities
- issuerSpyre Therapeutics, Inc.
Subject of the insider transaction disclosure (SYRE).
- insiderTurtle Cameron
CEO and director who sold shares under a pre-arranged 10b5-1 plan.
